# TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc. is a company headquartered in Austin, TX, United States.

## Company overview

- **Legal name:** TFF Pharmaceuticals, Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Austin, TX, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001733413

## About

TFF Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001733413, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-28, it reported annual revenue of USD 733,871; net income of USD -21,243,231; total assets of USD 12,027,316 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $733,871 (USD 733,871)
- **Net income:** -$21.2M (USD -21,243,231)
- **Total assets:** $12.0M (USD 12,027,316)
- **Cash and equivalents:** $5.5M (USD 5,478,113)
- **Operating cash flow:** -$16.0M (USD -16,038,195)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $495,805 (USD 495,805)
- **Net income:** -$31.8M (USD -31,770,062)
- **Total assets:** $24.1M (USD 24,120,215)
- **Cash and equivalents:** $16.6M (USD 16,612,315)
- **Operating cash flow:** -$27.3M (USD -27,342,160)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $88,161 (USD 88,161)
- **Net income:** -$31.0M (USD -31,038,712)
- **Total assets:** $40.7M (USD 40,697,811)
- **Cash and equivalents:** $33.8M (USD 33,794,672)
- **Operating cash flow:** -$29.6M (USD -29,556,971)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$18.6M (USD -18,567,234)
- **Total assets:** $38.7M (USD 38,661,842)
- **Cash and equivalents:** $35.3M (USD 35,300,805)
- **Operating cash flow:** -$16.6M (USD -16,615,589)

## Recent SEC filings

- Form 8-K — filed 2025-03-06 — period 2025-03-03 — CURRENT REPORT
- Form 8-K — filed 2025-02-03 — period 2025-01-28 — CURRENT REPORT
- Form DEF 14A — filed 2024-12-23 — period 2025-01-28 — PROXY STATEMENT
- Form 8-K — filed 2024-12-10 — period 2024-12-04 — CURRENT REPORT
- Form 10-Q — filed 2024-11-20 — period 2024-09-30 — QUARTERLY REPORT
- Form 8-K — filed 2024-11-14 — period 2024-11-14 — CURRENT REPORT
- Form SC 13G — filed 2024-11-14
- Form 8-K — filed 2024-08-14 — period 2024-08-14 — CURRENT REPORT
- Form 10-Q — filed 2024-08-14 — period 2024-06-30 — QUARTERLY REPORT
- Form 8-K — filed 2024-08-06 — period 2024-08-06 — CURRENT REPORT
- Form 8-K — filed 2024-07-01 — period 2024-06-26 — CURRENT REPORT
- Form 8-K — filed 2024-06-07 — period 2024-06-04 — CURRENT REPORT

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/tff-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology